ReviewInternational journal of chronic obstructive pulmonary disease2026
Inhaled Therapy Adherence in COPD:A COM-B-Based Narrative Review of Determinants and Intervention Strategies.
Review in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Medication adherence is defined as the extent to which patients take medications as prescribed by their healthcare providers, encompassing three critical dimensions: initiation (starting the prescribed therapy), implementation (taking doses correctly as scheduled), and persistence (continuing treatment for the recommended duration). Long-term management of chronic obstructive pulmonary disease (COPD) relies heavily on inhalation therapy; however, real-world adherence remains suboptimal, with reported medication possession ratios (MPR) typically ranging from 40% to 60% in observational studies. Poor adherence is associated with increased exacerbation frequency, accelerated lung function decline, and substantial healthcare costs. Purpose: Based on the Capability-Opportunity-Motivation-Behaviour (COM-B) model, this narrative review aims to summarize and conceptually organize existing literature on measurement methods, epidemiological status, influencing factors, and intervention strategies for inhalation medication adherence in COPD patients, with particular emphasis on adherence differences between single-inhaler triple therapy (SITT) and multiple-inhaler triple therapy (MITT). Methods: A narrative review methodology was employed, utilizing purposing literature search combined with citation back-tracking. Observational studies and randomized controlled trials from PubMed, CNKI, and other databases (up to December 2024) were included, with influencing factors categorized according to COM-B dimensions. Quantitative estimates reported in this review are derived from individual observational studies with heterogeneous designs and populations, and should be interpreted as illustrative ranges rather than pooled or definitive values. Quantitative estimates are derived from heterogeneous observational studies and should be interpreted as illustrative rather than pooled values. The non-systematic, purposing nature of this review limits comprehensive generalizability. Results: Across the heterogeneous observational studies included in this review, MPR ≥80% was achieved by approximately 30% to 50% of patients in reported cohorts, while inhalation technique error rates were reported as illustrative ranges of 30% to 50%. The COM-B framework suggests that adherence deficits arise from the interplay of capability limitations (operational skill deficits), opportunity constraints (with the MITT associated with an illustrative range of approximately 12% to 14% lower MPR compared with SITT in reported real-world studies), and motivational barriers (with depression and anxiety associated with approximately 20% to 25% reductions in adherence in individual cohorts). In observational data, higher adherence has been associated with a reported 51% reduction in exacerbation-related hospitalization risk and an attenuation of forced expiratory volume in 1 second (FEV Conclusion: Inhalation medication adherence in COPD represents a multidimensional behavioral syndrome. This review proposes that transitioning from traditional "one-size-fits-all" education models to precision stratified interventions based on the COM-B framework may enable more individualized chronic disease management, though further empirical validation of phenotype-stratified interventions is warranted. This phenotype-stratified model represents a conceptual framework advanced by the authors to stimulate future research, rather than an empirically validated clinical tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.